Hemato-Oncology Testing Market Size, Share & Trends Analysis Report 2025-2030 Featuring Key Players Roche, Abbott, Entrogen, Qiagen, And Cepheid (Danaher) Among Others

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in the hemato-oncology testing market include rising lymphoma and myeloma cases, personalized therapy demand, and advanced molecular diagnostics. Emerging technologies like single-cell sequencing and long-read sequencing enhance diagnostic precision, thus driving market growth and improving patient outcomes.

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Hemato-Oncology Testing Market Size, Share & Trends Analysis 2025-2030" has been added to ResearchAndMarkets.com's offering.

The global hemato oncology testing market is poised for significant growth, with market size estimated to reach USD 3.60 billion in 2024 and projected to rise to USD 7.44 billion by 2030, at a CAGR of 12.99% from 2025 to 2030. This growth is driven by several factors, including the increasing prevalence of lymphoma and myeloma, a surge in demand for personalized therapy, advancements in molecular diagnostics, and enhanced drug-diagnostics co-development.

The integration of advanced molecular diagnostics has revolutionized hemato-oncology, providing precision in the detection, diagnosis, and treatment of blood cancers. Modern techniques like real-time PCR, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) are instrumental in identifying genetic alterations. For instance, CML is diagnosed using PCR-based tests, while NGS panels aid in identifying mutations in AML and ALL, crucial for devising treatment strategies. Additionally, the JAK2 V617F mutation is pivotal in diagnosing polycythemia vera.

Recent advancements include single-cell sequencing, optical genome mapping (OGM), and long-read sequencing. These technologies offer finer resolution, enabling better insights into tumor dynamics. OGM, for example, allows comprehensive cytogenomic profiling, identifying significant variants and streamlining workflows, thereby improving diagnostic precision. Notably, a study at Lille University Hospital demonstrated OGM's 93% concordance with traditional FISH, revealing additional genomic variants.

In 2024, Oxford Gene Technology introduced the SureSeq Myeloid Fusion Panel, an RNA-based NGS tool enhancing AML diagnosis by identifying over 30 critical gene fusions. Its seamless integration into NGS workflows enhances classification capabilities and reduces turnaround times in clinical settings. Further, long-read sequencing technologies from Pacific Biosciences and Oxford Nanopore are reshaping diagnostics by providing comprehensive genomic profiles, surpassing the limitations of short-read NGS.

These advanced molecular tools are redefining the hemato-oncology diagnostics landscape, empowering personalized medicine and promising improved patient outcomes. Continued innovation holds the potential to boost diagnostic speed, accuracy, and cost-effectiveness.

Lymphoma and myeloma remain among the most indicated hematologic malignancies in the United States, significantly impacting the overall cancer landscape.

Report Segmentation

The report forecasts revenue growth and analyzes market trends across various sub-markets from 2018 to 2030. It segments the global market by cancer type, product, technology, end-use, and region.

Why should you buy this report?

• Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
• Competitive Landscape: Explore the market presence of key players worldwide.
• Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
• Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

• Market intelligence to enable effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segment and regional revenue forecasts for market assessment
• Competition strategy and market share analysis
• Product innovation listing for you to stay ahead of the curve

Key Attributes

Report Attribute	Details
No. of Pages	120
Forecast Period	2024-2030
Estimated Market Value (USD) in 2024	$3.6 Billion
Forecasted Market Value (USD) by 2030	$7.44 Billion
Compound Annual Growth Rate	12.9%
Regions Covered	Global

Key Topics Covered

• Chapter 1. Methodology and Scope
  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
• Chapter 2. Executive Summary
  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights
• Chapter 3. Hemato oncology testing Market Variable Trends & Scope
  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
  • 3.3. Hemato oncology testing Market Analysis Tools
• Chapter 4. Hemato oncology testing Market: Cancer Estimates & Trend Analysis
  • 4.1. Segment Dashboard
  • 4.2. Hemato oncology testing Market Cancer Movement Analysis
  • 4.3. Hemato oncology testing Market Size & Trend Analysis, By Cancer, 2018-2030
  • 4.4. Leukemia
  • 4.5. Lymphoma
  • 4.6. Myeloproliferative Neoplasms
  • 4.7. Other Cancers
• Chapter 5. Hemato oncology testing Market: Product Estimates & Trend Analysis
  • 5.1. Segment Dashboard
  • 5.2. Hemato oncology testing Market Product Movement Analysis
  • 5.3. Hemato oncology testing Market Size & Trend Analysis, By Product, 2018-2030
• Chapter 6. Hemato oncology testing Market: Technology Estimates & Trend Analysis
  • 6.1. Segment Dashboard
  • 6.2. Hemato oncology testing Market Technology Movement Analysis
  • 6.3. Hemato oncology testing Market Size & Trend Analysis, By Technology, 2018-2030
• Chapter 7. Hemato oncology testing Market: End Use Estimates & Trend Analysis
  • 7.1. Segment Dashboard
  • 7.2. Hemato oncology testing Market End Use Movement Analysis
  • 7.3. Hemato oncology testing Market Size & Trend Analysis, By End Use, 2018-2030
• Chapter 8. Competitive Landscape
  • 8.1. Market Participant Categorization
  • 8.2. Participants Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Market Position Analysis, 2024
  • 8.6. Strategy Mapping
  • 8.7. Company Profiles
  • 8.8. List of Other Market Players
• Chapter 9. Key Takeaways

Companies Profiled

• F. Hoffmann-La Roche Ltd.
• Abbott
• EntroGen Inc.
• Qiagen N.V.
• Cepheid (Danaher Corporation)
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Amoy Diagnostics Co. Ltd.
• ASURAGEN, INC
• ArcherDX, Inc. (IDT)

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Hemato Oncology Testing Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN02092025004107003653ID1110005716